West Pharmaceutical Services, Inc.
HealthcareNYSE:WST · New York Stock Exchange
-$1.52 today
Vol 0.36M · Avg 0.86M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
15.5%
avg 17.0%
ROIC
13.6%
avg 14.3%
ROA
11.6%
avg 12.2%
Analysis
ROE is currently the strongest return metric at 15.5% versus its period average of 17.0%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert W. McMahon | Senior Vice President & Chief Financial Officer | $4.50M | — | 57 | $0.00 | <0.01% |
Eric Green | Non-Independent Chair of the Board, President & Chief Executive Officer | $2.71M | — | 56 | $16,630.00 | 0.02% |
Devesh Mathur | Senior Vice President & Chief Technology Officer | $972,092.00 | — | — | — | — |
Shane Campbell | SVP & Chief Proprietary Segment Officer | $949,834.00 | — | 45 | $1,417.41 | <0.01% |
Annette F. Favorite | Chief Human Resources Officer & Senior Vice President | $927,847.00 | — | 61 | $5,635.00 | <0.01% |
Kathy DePadua | Senior Vice President and Chief Quality & Regulatory Officer | — | — | — | — | — |
Michele Polinsky | Vice President of Global Communications | — | — | — | — | — |
Chad R. Winters | Vice President of Finance & Chief Accounting Officer | — | — | 47 | $1,522.81 | <0.01% |
John Sweeney | Vice President of Investor Relations | — | — | — | $45,358.72 | 0.06% |
Norman Finch | Senior VP, General Counsel & Corporate Secretary | — | — | 61 | $0.00 | <0.01% |
Rudy Poussot | Senior Vice President of Strategy & Corporate Development | — | — | 56 | $1,040.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$1.13M
Net Sentiment
$1.13M
Net selling
Most Active
Winters Chad
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 27, 2026 | Winters Chad Direct | Sell | 896 | $300.67 | $269,399.24 | |
| Apr 27, 2026 | Favorite Annette F Direct | Sell | 2.8K | $305.20 | $859,753.47 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $1.13M over the last 12 months. That adds up to net selling of $1.13M. Winters Chad was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +4.2% | +16.2% (15yr)1 analysts |
| Revenue | N/A | N/A | +3.4% | +7.5% (15yr)7 analysts |
| Net Income | N/A | N/A | +5.8% | +16.2% (15yr)7 analysts |
| EBIT | N/A | N/A | -2.7% | +14.4% (15yr)7 analysts |
Analysis
Recent growth has been strongest in Net Income at +5.8% over three years. Forward estimates point to EPS at +16.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Illumina, Inc.
NASDAQ:ILMN
$24.35B
Waters Corporation
NYSE:WAT
$23.17B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
Labcorp Holdings Inc.
NYSE:LH
$21.83B
Incyte Corporation
NASDAQ:INCY
$21.68B
STERIS plc
NYSE:STE
$20.26B
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
$17.13B
Hologic, Inc.
HOLX
$16.97B
Medpace Holdings, Inc.
NASDAQ:MEDP
$13.35B
The Cooper Companies, Inc.
NASDAQ:COO
$13.24B
Who manages WST?
West Pharmaceutical Services, Inc. (WST) lists 11 active executives. The top listed executive is Shane Campbell, SVP & Chief Proprietary Segment Officer.
Are WST insiders buying or selling?
Recent insider activity shows net selling of $38.15M.
Explore More
Continue the stock analysis
Jump to another research area for this company.